TrialBreast cancer research and treatment2020

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).

Richard S Finn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.